Ortivus AB (publ) (ORTI-A.ST)
SEK 2.8
(6.06%)
SEK 2.8
(6.06%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 84.08 Million SEK | -19.55% |
| 2022 | 104.5 Million SEK | 10.86% |
| 2021 | 94.27 Million SEK | -12.37% |
| 2020 | 107.58 Million SEK | 111.58% |
| 2019 | 50.84 Million SEK | -2.59% |
| 2018 | 52.2 Million SEK | -11.22% |
| 2017 | 58.79 Million SEK | -20.84% |
| 2016 | 74.27 Million SEK | 2.29% |
| 2015 | 72.61 Million SEK | 4.69% |
| 2014 | 69.36 Million SEK | 92.12% |
| 2013 | 36.1 Million SEK | -40.53% |
| 2012 | 60.71 Million SEK | 32.71% |
| 2011 | 45.74 Million SEK | -4.14% |
| 2010 | 47.72 Million SEK | -54.56% |
| 2009 | 105.03 Million SEK | 26.38% |
| 2008 | 83.11 Million SEK | -48.82% |
| 2007 | 162.4 Million SEK | -18.7% |
| 2006 | 199.77 Million SEK | 15.11% |
| 2005 | 173.55 Million SEK | 23.25% |
| 2004 | 140.8 Million SEK | -19.63% |
| 2003 | 175.2 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 22.05 Million SEK | 13.63% |
| 2024 Q2 | 17.68 Million SEK | -19.81% |
| 2023 Q4 | 19.4 Million SEK | 17.11% |
| 2023 Q1 | 27.98 Million SEK | -16.09% |
| 2023 Q3 | 16.57 Million SEK | -19.98% |
| 2023 Q2 | 20.7 Million SEK | -26.01% |
| 2023 FY | 84.08 Million SEK | -19.55% |
| 2022 Q2 | 26.35 Million SEK | 7.02% |
| 2022 Q1 | 24.62 Million SEK | 8.95% |
| 2022 Q3 | 20.18 Million SEK | -23.42% |
| 2022 Q4 | 33.35 Million SEK | 65.29% |
| 2022 FY | 104.5 Million SEK | 10.86% |
| 2021 FY | 94.27 Million SEK | -12.37% |
| 2021 Q2 | 23.6 Million SEK | 0.25% |
| 2021 Q3 | 24.52 Million SEK | 3.93% |
| 2021 Q4 | 22.6 Million SEK | -7.86% |
| 2021 Q1 | 23.54 Million SEK | 7.68% |
| 2020 Q3 | 25.35 Million SEK | -36.95% |
| 2020 Q4 | 21.86 Million SEK | -13.76% |
| 2020 Q1 | 20.16 Million SEK | 17.89% |
| 2020 FY | 107.58 Million SEK | 111.58% |
| 2020 Q2 | 40.2 Million SEK | 99.43% |
| 2019 Q3 | 10.4 Million SEK | -11.51% |
| 2019 Q1 | 11.58 Million SEK | -19.29% |
| 2019 Q4 | 17.1 Million SEK | 64.32% |
| 2019 Q2 | 11.76 Million SEK | 1.55% |
| 2019 FY | 50.84 Million SEK | -2.59% |
| 2018 Q3 | 13.25 Million SEK | 7.48% |
| 2018 Q1 | 12.26 Million SEK | -28.8% |
| 2018 Q4 | 14.34 Million SEK | 8.26% |
| 2018 Q2 | 12.33 Million SEK | 0.51% |
| 2018 FY | 52.2 Million SEK | -11.22% |
| 2017 FY | 58.79 Million SEK | -20.84% |
| 2017 Q4 | 17.23 Million SEK | 46.36% |
| 2017 Q3 | 11.77 Million SEK | -14.72% |
| 2017 Q2 | 13.8 Million SEK | -13.68% |
| 2017 Q1 | 15.99 Million SEK | -30.25% |
| 2016 Q1 | 14.13 Million SEK | 2.43% |
| 2016 Q3 | 21.74 Million SEK | 40.6% |
| 2016 Q2 | 15.46 Million SEK | 9.42% |
| 2016 Q4 | 22.92 Million SEK | 5.44% |
| 2016 FY | 74.27 Million SEK | 2.29% |
| 2015 FY | 72.61 Million SEK | 4.69% |
| 2015 Q3 | 14.38 Million SEK | -37.91% |
| 2015 Q2 | 23.16 Million SEK | 8.94% |
| 2015 Q1 | 21.26 Million SEK | 18.64% |
| 2015 Q4 | 13.8 Million SEK | -4.06% |
| 2014 Q1 | 15.42 Million SEK | 87.97% |
| 2014 FY | 69.36 Million SEK | 92.12% |
| 2014 Q4 | 17.92 Million SEK | -8.87% |
| 2014 Q3 | 19.67 Million SEK | 20.31% |
| 2014 Q2 | 16.35 Million SEK | 6.02% |
| 2013 FY | 36.1 Million SEK | -40.53% |
| 2013 Q2 | 9.84 Million SEK | -1.21% |
| 2013 Q3 | 8.08 Million SEK | -17.85% |
| 2013 Q4 | 8.2 Million SEK | 1.43% |
| 2013 Q1 | 9.96 Million SEK | -28.91% |
| 2012 Q3 | 18.04 Million SEK | -9.74% |
| 2012 Q1 | 8.65 Million SEK | -38.1% |
| 2012 Q2 | 19.98 Million SEK | 130.83% |
| 2012 FY | 60.71 Million SEK | 32.71% |
| 2012 Q4 | 14.02 Million SEK | -22.29% |
| 2011 Q2 | 9.77 Million SEK | -38.93% |
| 2011 Q3 | 5.98 Million SEK | -38.76% |
| 2011 Q4 | 13.98 Million SEK | 133.72% |
| 2011 FY | 45.74 Million SEK | -4.14% |
| 2011 Q1 | 16 Million SEK | -14.66% |
| 2010 Q1 | 10.09 Million SEK | 0.0% |
| 2010 FY | 47.72 Million SEK | -54.56% |
| 2010 Q4 | 18.75 Million SEK | 273.21% |
| 2010 Q2 | 13.86 Million SEK | 37.34% |
| 2010 Q3 | 5.02 Million SEK | -63.75% |
| 2009 FY | 105.03 Million SEK | 26.38% |
| 2008 FY | 83.11 Million SEK | -48.82% |
| 2007 FY | 162.4 Million SEK | -18.7% |
| 2006 FY | 199.77 Million SEK | 15.11% |
| 2005 FY | 173.55 Million SEK | 23.25% |
| 2004 FY | 140.8 Million SEK | -19.63% |
| 2003 FY | 175.2 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AddLife AB (publ) | 9.68 Billion SEK | 99.132% |
| Biotage AB (publ) | 1.86 Billion SEK | 95.484% |
| Bonesupport Holding AB (publ) | 591.07 Million SEK | 85.775% |
| Doxa AB (publ) | 9.9 Million SEK | -749.303% |
| Elekta AB (publ) | 18.11 Billion SEK | 99.536% |
| iZafe Group AB (publ) | 1.82 Million SEK | -4514.764% |
| Ortivus AB (publ) | 84.08 Million SEK | 0.0% |
| Q-linea AB (publ) | 4.44 Million SEK | -1793.716% |
| S2Medical AB (publ) | 6.97 Million SEK | -1106.094% |
| Synsam AB (publ) | 5.9 Billion SEK | 98.576% |